Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17444748 | 0.89 | PARP14 (0.63) | ALDH1A1MAPTSOAT1LMNARAB9A | |
| SCHEMBL5213400 | 0.87 | ALDH1A1 (0.59) | ALDH1A1MAPTSOAT1L3MBTL1HTT | |
| SCHEMBL26646514 | 0.86 | SOAT1 (0.78) | ALDH1A1MAPTSOAT1L3MBTL1HTT | |
| SCHEMBL5216395 | 0.84 | ALDH1A1 (0.61) | ALDH1A1MAPTSOAT1L3MBTL1LMNA | |
| SCHEMBL11741667 | 0.84 | MAPT (0.65) | ALDH1A1MAPTSOAT1L3MBTL1HTT | |
| SCHEMBL11842346 | 0.84 | ALDH1A1 (0.53) | ALDH1A1MAPTSOAT1L3MBTL1HTT | |
| SCHEMBL8619629 | 0.82 | MAPK1 (0.60) | ALDH1A1MAPTHTTLMNARAB9A | |
| SCHEMBL3172180 | 0.82 | HTT (0.62) | ALDH1A1MAPTSOAT1L3MBTL1HTT | |
| SCHEMBL28701426 | 0.82 | MAPT (0.67) | ALDH1A1MAPTSOAT1L3MBTL1HTT | |
| SCHEMBL789303 | 0.82 | MAPT (0.62) | ALDH1A1MAPTSOAT1L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-7244847-B2 | Benzimidazole compounds | ISIS PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1567502-A1 | SUBSTITUTED DIHYDROPHENANTHRIDINESUL FONAMIDES | Wyeth (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050631-A1 | SUBSTITUTED DIHYDROPHENANTHRIDINESUL FONAMIDES | WYETH (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | ALDH1A1 1505/4885MAPT 2212/4885SOAT1 3525/4885 |
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | HAMP, SLC40A1, FTH1 | ALDH1A1 796/4885MAPT 4745/4885SOAT1 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.